Oral Semaglutide 25 mg Achieves Equivalent Exposure to SC 2.4 mg, Demonstrates Superior Weight Loss in Simulated Trials
Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis.
Study Design
Population
N=12 RCTs, total n=8,742 T2D patients
Intervention
Oral semaglutide 25 mg
Comparator
Subcutaneous semaglutide 2.4 mg
Abstract
Oral semaglutide 25 mg achieved exposure similar to SC 2.4 mg and led to greater weight loss in simulated studies, according to a meta-analysis.